Mirati Therapeutics Inc

MRTX:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EST
214.45UNCH (UNCH)
Volume
12,060
Close
214.45quote price arrow up+1.52 (+0.71%)
Volume
311,456
52 week range
66.01 - 249.42

...

Loading . . .

KEY STATS

  • Open211.40
  • Day High214.75
  • Day Low211.15
  • Prev Close212.93
  • 52 Week High249.42
  • 52 Week High Date12/14/20
  • 52 Week Low66.01
  • 52 Week Low Date03/18/20
  • Market Cap10,782.55M
  • Shares Out50.28M
  • 10 Day Average Volume0.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • 1 Year % Change135.69

RATIOS/PROFITABILITY

  • EPS (TTM)-7.70
  • P/E (TTM)-27.84
  • Fwd P/E (NTM)-24.29
  • EBITDA (MRQ)-337.15M
  • ROE (MRQ)-66.82%
  • Revenue (MRQ)12.22M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,694.82%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date02/23/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Mirati Therapeutics Inc News

There is no recent news for this security.

Latest MRTX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development...
Faheem Hasnain
Chairman
Charles Baum M.D., Ph.D.
President
Daniel Faga
Chief Operating Officer
James Christensen Ph.D.
Executive Vice President
Benjamin Hickey
Executive Vice President
Address
9393 Towne Centre Dr Ste 200
San Diego, CA
92121-3070
United States